


The invention relates to the chemistry of natural compounds and medicinal chemistry, in particular to an *ent*-kaurenoic acid derivative containing a pyrrolidine functional group, which exhibits selective cytotoxic properties in relation to human cancer cells and can be used as a chemotherapeutic agent for the treatment of oncological diseases.

According to the invention, claimed is the compound (16R)-spiro[pyrrolidine-2',16-*ent*-17-norkauran]-19-oic acid methyl ester with the structural formula:



The claimed compound has selective cytotoxic activity against the Hap-1 and K-562 (chronic myeloid leukemia), NCI-H460 (lung carcinoma), DND-41 (acute lymphoblastic leukemia), HL-60 (acute myeloid leukemia) and Z -138 (non-Hodgkin lymphoma) tumor cells line.

Claims: 2

Fig.: 4